Kava für Hyperarousal and Cognitive Insomnia

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dkava\u0026condition\u003Dhyperarousal\u002Dinsomnia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Fazit

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

Key Study Findings

Case Reports n=1 6 weeks

Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.

Dose: None vs.: None Outcome: acute kava dermopathy with sebaceous gland necrosis Wirkung: None None

Population: 41-year-old Australian woman consuming kava for anxiety and insomnia

Case Reports n=1 Open-label

Severe kava withdrawal managed with phenobarbital.

Dose: None vs.: None Outcome: Resolution of kava withdrawal symptoms Wirkung: None None

Population: 45-year-old man with kava and kratom withdrawal

Other Double-blind

The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …

Dose: AB-free kava extract vs.: Placebo Outcome: Tobacco cessation via stress/insomnia management Wirkung: None None

Population: Adult smokers (trial protocol)

Controlled Clinical Trial

Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.

Dose: None vs.: Vehicle control Outcome: Acute oral toxicity, antinociceptive activity Wirkung: None None

Population: Animal model

Systematic Review

The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.

Dose: None vs.: None Outcome: Sleep quality improvement Wirkung: None None

Population: Insomnia patients

Review

Calm Down With Kava: What Clinicians Need to Know.

Dose: None vs.: None Outcome: None Wirkung: None None

Population: Kava users

Key Statistics

Studien

2043

Teilnehmer

↔

Mixed

Bewertung

Referenced Papers

Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption. Case Report

The Medical journal … 2026

Severe kava withdrawal managed with phenobarbital. Case Report

The American journal … 2025 1 Zitierungen

The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and insomnia: study protocol for a … Other

BMC complementary medicine … 2024 1 Zitierungen

An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. Review

Journal of clinical … 2022 27 Zitierungen

The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review. Review

Cureus 2022 17 Zitierungen

Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain. Other

Natural product research 2022 3 Zitierungen

Calm Down With Kava: What Clinicians Need to Know. Other

Journal of psychosocial … 2022 2 Zitierungen

Nutraceuticals for Sleep Disorders. Review

Combinatorial chemistry & … 2021 16 Zitierungen

The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … Other

Journal of clinical … 2020 17 Zitierungen

Enzymes and Pathways of Kavain Bioactivation and Biotransformation. Other

Chemical research in … 2019 6 Zitierungen

Natural Products from Single Plants as Sleep Aids: A Systematic Review. Systematic Review

Journal of medicinal … 2018 19 Zitierungen

Herbal medicine for insomnia: A systematic review and meta-analysis. Meta-Analysis

Sleep medicine reviews 2015 152 Zitierungen

Psychophytomedicine: an overview of clinical efficacy and phytopharmacology for treatment of depression, anxiety and insomnia. Review

Holistic nursing practice 2014 10 Zitierungen

Toxicokinetics of kava. Other

Advances in pharmacological … 2011 79 Zitierungen

Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. Other

FASEB journal : … 2010 110 Zitierungen

Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. Review

Journal of psychopharmacology … 2005 176 Zitierungen

An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. RCT

Medicine 2005 128 Zitierungen

Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. Other

Psychopharmacology 2005 36 Zitierungen

Safety and efficacy of herbal sedatives in cancer care. Review

Integrative cancer therapies 2004 59 Zitierungen

Saccade and cognitive impairment associated with kava intoxication. Other

Human psychopharmacology 2003 45 Zitierungen

Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents. Review

General hospital psychiatry 2002 38 Zitierungen

Kava and valerian in the treatment of stress-induced insomnia. Other

Phytotherapy research : … 2001 74 Zitierungen

Stress-induced insomnia treated with kava and valerian: singly and in combination. Other

Human psychopharmacology 2001 52 Zitierungen

[Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract]. Case Report

Der Hautarzt; Zeitschrift … 1996 22 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

sleep:: 120-250 mg kavalactones/day, 1-2 hrs before bed

Obergrenze: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

In der Forschung untersuchte Dosierungen

Dosierung	Dauer	Wirkung	N
None	6 weeks	Negative	1
None	--	Positive	1
AB-free kava extract	--	Mixed	--
None	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Mixed	--
not specified	--	Positive	--

Beste Einnahmezeit: 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision

Safety & Side Effects

Gemeldete Nebenwirkungen

⚠ Drowsiness and reduced coordination
⚠ Hepatotoxicity (rare but serious — consult healthcare provider)
⚠ Skin rash (kava dermopathy) with chronic high-dose use
⚠ GI discomfort

Bekannte Wechselwirkungen

● Alcohol — increased hepatotoxicity risk and CNS depression
● Hepatotoxic medications (acetaminophen, statins) — additive liver stress
● Benzodiazepines and sedatives — additive CNS depression
● CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
● Levodopa and dopaminergic drugs — kava may reduce efficacy

Tolerierbare Höchstaufnahmemenge: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Kava help with Hyperarousal and Cognitive Insomnia?

Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support Hyperarousal and Cognitive Insomnia management. Our evidence grade is A (Strong Evidence).

How much Kava should I take for Hyperarousal and Cognitive Insomnia?

Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Kava?

Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Kava and Hyperarousal and Cognitive Insomnia?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.

Related Evidence

Andere Inhaltsstoffe für Hyperarousal and Cognitive Insomnia

Skullcap B Magnesium L-Threonate D

Kava für andere Beschwerden

Insomnie A Angstbedingte Schlafprobleme A

Kurzfazit

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

Evidence Strength92%

High confidence

Studienübersicht

RCT (1)Meta (1)Other (21)

Alternativen vergleichen

Sehen Sie, wie andere Inhaltsstoffe bei dieser Beschwerde abschneiden.

Alle Inhaltsstoffe ansehen für Hyperarousal and Cognitive Insomnia

Mehr erfahren

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.